Bone Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Bone Cancer, including details on symptoms, types, treatment.

Volume 6 (2009), Issue 6 (June)

1. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.
   Lancet Oncol, 10(6): 606-14. [Abstract] [Full-text]
2. Functional outcomes after limb-salvage surgery and endoprosthetic reconstruction with an expandable prosthesis: a report of 4 cases.
   Arch Phys Med Rehabil, 90(6): 1039-47. [Abstract] [Full-text]
3. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
   Cancer Chemother Pharmacol, 64(2): 407-12. [Abstract] [Full-text]
4. Below-knee amputation through a joint-sparing proximal tibial replacement for recurrent tumour.
   J Bone Joint Surg Br, 91(6): 815-9. [Abstract] [Full-text]
5. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma.
   J Bone Joint Surg Br, 91(6): 784-8. [Abstract] [Full-text]
6. Cytogenetic and real-time quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma.
   Cancer Genet Cytogenet, 192(1): 1-9. [Abstract] [Full-text]
7. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
   Cancer Chemother Pharmacol, 64(2): 371-7. [Abstract] [Full-text]
8. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
   Cancer Chemother Pharmacol, 64(2): 401-6. [Abstract] [Full-text]
9. Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases.
   Int J Radiat Oncol Biol Phys, 74(3): 723-31. [Abstract] [Full-text]
10. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas.
    Int J Radiat Oncol Biol Phys, 74(3): 732-9. [Abstract] [Full-text]
11. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer.
    Cancer Chemother Pharmacol, 64(2): 341-6. [Abstract] [Full-text]
12. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma.
    Int J Radiat Oncol Biol Phys, 74(3): 740-6. [Abstract] [Full-text]
13. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Prostate, 69(10): 1101-8. [Abstract] [Full-text]
14. Atypical sinonasal Schwannomas: a difficult diagnostic challenge.
    Auris Nasus Larynx, 36(4): 482-6. [Abstract] [Full-text]
15. Infarct-associated bone sarcomas.
    Clin Orthop Relat Res, 467(7): 1820-5. [Abstract] [Full-text]
16. Case report: histologic study of a human epiphyseal transplant at 3 years after implantation.
    Clin Orthop Relat Res, 467(7): 1915-20. [Abstract] [Full-text]
17. Telescope allograft method to reconstitute the diaphysis in limb salvage surgery.
    Clin Orthop Relat Res, 467(7): 1813-9. [Abstract] [Full-text]
18. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis.
    Cancer Lett, 281(1): 32-41. [Abstract] [Full-text]
19. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation.
    Br J Cancer, 100(12): 1957-65. [Abstract] [Full-text]
20. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.
    Br J Cancer, 100(12): 1846-51. [Abstract] [Full-text]
21. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants.
    Proc Natl Acad Sci U S A, 106(23): 9385-90. [Abstract] [Full-text]
22. Giant cell tumour of bone.
    Curr Opin Oncol, 21(4): 338-44. [Abstract] [Full-text]
23. Utilization of positron emission tomography in the management of patients with sarcoma.
    Curr Opin Oncol, 21(4): 345-51. [Abstract] [Full-text]
24. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
    J Pathol, 218(3): 399-408. [Abstract] [Full-text]
25. MR imaging of primary bone tumors and tumor-like conditions in children.
    Magn Reson Imaging Clin N Am, 17(3): 469-87, vi. [Abstract] [Full-text]
26. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
    Cancer Res, 69(12): 5007-14. [Abstract] [Full-text]
27. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.
    Genes Chromosomes Cancer, 48(8): 679-93. [Abstract] [Full-text]
28. Reconstruction of oromandibular defects by vascularized free flaps: the radial forearm free flap and fibular free flap as major donor sites.
    J Oral Maxillofac Surg, 67(7): 1473-7. [Abstract] [Full-text]
29. Nonvascularized bone grafts for segmental reconstruction of the mandible--a reappraisal.
    J Oral Maxillofac Surg, 67(7): 1446-52. [Abstract] [Full-text]
30. Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group.
    J Surg Oncol, 100(1): 48-54. [Abstract] [Full-text]
31. Solitary plasmocytoma: improvement in critical organs sparing by means of helical tomotherapy.
    Eur J Haematol, 83(1): 66-71. [Abstract] [Full-text]
32. 18F-FDG PET evaluation of sinonasal papilloma.
    AJR Am J Roentgenol, 193(1): 214-7. [Abstract] [Full-text]
33. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.
    Int J Cancer, 125(4): 879-86. [Abstract] [Full-text]
34. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
    Int J Cancer, 125(4): 851-60. [Abstract] [Full-text]
35. Optimal treatment planning for skull base chordoma: photons, protons, or a combination of both?
    Int J Radiat Oncol Biol Phys, 74(4): 1033-9. [Abstract] [Full-text]
36. The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network.
    Int J Radiat Oncol Biol Phys, 74(4): 1114-20. [Abstract] [Full-text]
37. Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain.
    Anesthesiology, 111(1): 173-86. [Abstract] [Full-text]
38. Vertebral metastases with high risk of symptomatic malignant spinal cord compression.
    Jpn J Clin Oncol, 39(7): 431-4. [Abstract] [Full-text]
39. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
    Jpn J Clin Oncol, 39(7): 418-24. [Abstract] [Full-text]
40. Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas.
    Am J Pathol, 175(1): 376-91. [Abstract] [Full-text]
41. Bilateral anterior inferior iliac spine avulsion in an adolescent soccer player: a typical imitator of malignant bone lesions.
    South Med J, 102(7): 758-60. [Abstract] [Full-text]
42. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
    Cancer, 115(13): 2980-7. [Abstract] [Full-text]
43. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients.
    Laryngoscope, 119(7): 1412-6. [Abstract] [Full-text]
44. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
    Lung Cancer, 65(2): 219-22. [Abstract] [Full-text]
45. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro.
    Exp Cell Res, 315(14): 2333-42. [Abstract] [Full-text]
46. Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.
    Exp Cell Res, 315(14): 2442-52. [Abstract] [Full-text]

© 2004-2011 Bone Cancer Research Today. All Rights Reserved.